Hexvix (Hexaminolevulinate)

Hexvix is indicated for the detection of non‑muscle invasive bladder cancer during cystoscopic evaluation. By highlighting malignant tissue, it assists urologists in identifying lesions that may be missed under white‑light inspection.

• Intravesical administration before blue‑light cystoscopy to improve visualization of carcinoma in situ.
• Use in patients undergoing surveillance for recurrent superficial bladder tumors.
• Application in initial diagnostic work‑up of patients with hematuria when bladder cancer is suspected.
• Adjunct to standard white‑light cystoscopy to increase diagnostic sensitivity.
• May be employed in combination with transurethral resection to guide tissue sampling.

• Hexvix contains hexaminolevulinate, a prodrug that enters urothelial cells and is metabolized within the heme biosynthetic pathway to protoporphyrin IX. The accumulated porphyrin preferentially localizes in malignant cells because of altered enzymatic activity, and it emits fluorescence when excited by blue light (380–440 nm). This optical contrast enables clinicians to differentiate cancerous tissue from normal bladder mucosa during photodynamic diagnosis in real time.

Adverse reactions to Hexvix are generally related to the intravesical administration and the photosensitizing properties of hexaminolevulinate.

Common

• Mild bladder discomfort or urgency during or shortly after instillation.
• Transient hematuria or pink‑tinged urine observed within the first few hours.
• Temporary urinary frequency, dysuria, or suprapubic pressure.
• Mild erythema of the urethral or bladder mucosa.
• Short‑lasting bladder spasm that resolves without intervention.

Serious

• Severe systemic allergic reaction, including anaphylaxis, requiring emergency treatment.
• Prolonged bladder irritation that progresses to cystitis with fever or flank pain.
• Persistent urinary retention necessitating catheter placement or surgical intervention.
• Localized photosensitivity of peri‑urethral tissue after exposure to intense light sources.

Before using Hexvix, clinicians should evaluate patient history and bladder condition to minimize risks associated with intravesical photosensitizers.

• Confirm absence of active urinary tract infection or gross hematuria.
• Avoid use in patients with known hypersensitivity to hexaminolevulinate or similar porphyrin compounds.
• Ensure bladder capacity is adequate for the 50 mL instillation volume.
• Defer administration in pregnant or nursing women due to unknown fetal risk.
• Monitor patients for urinary symptoms during the observation period after instillation.
• Do not expose the bladder to intense external light sources for several hours post‑procedure.

Hexvix may interact with other agents that affect photosensitivity or bladder physiology.

Avoid

• Concurrent use of systemic photosensitizing drugs (e.g., porfimer sodium, aminolevulinic acid) that could amplify fluorescence reactions.
• Administration immediately after intravesical chemotherapy agents that irritate the bladder mucosa.
• Avoid simultaneous bladder instillation of agents that contain strong acids or bases, which may degrade the prodrug.

Use with caution

• Co‑administration of anticoagulants, as hematuria may be more pronounced.
• Use in patients receiving intravesical immunotherapy (e.g., BCG) due to overlapping bladder irritation.
• Concomitant use of drugs that alter urinary pH, which could affect hexaminolevulinate stability.
• Exercise caution when combining with diuretics, as increased urine flow may reduce contact time of the solution.
• Monitor closely when used alongside agents that modify bladder contractility.